A Study to Evaluate Tislelizumab Combined With Sitravatinib as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection

Inclusion Criteria: 1. Subjects with a histopathological or cytologically diagnosis of HCC 2. Subjects who have undergone a curative resection 3. High risk for HCC recurrence as protocol defined 4. No previous systematic treatment and locoregional therapy for HCC 5. Child-Pugh Score, Class A 6. ECOG performance status 0 or 1 7. Full recovery from surgical resection 8. Adequate organ function 9. Absence of major macrovascular invasion 10. No extrahepatic spread 11. Life expectancy of at least 6 months Exclusion Criteria: 1. Known fibrolamellar HCC, sarcomatoid HCC or mixed cholangiocarcinoma and HCC 2. Evidence of residual, recurrent, or metastatic disease 3. Known history of serious allergy to any component of tislelizumab or sitravatinib preparations 4. History of hepatic encephalopathy 5. Tumor thrombus in portal vein or superior mesenteric vein or inferior caval vein 6. Portal hypertension with bleeding esophageal or gastric varices within 6 months prior to initiation of treatment 7. Any bleeding or thrombotic disorder within 6 months prior to initiation of treatment 8. Any active malignancy within 2 years prior to the start of treatment 9. Active or history of autoimmune disease 10. Other acute or chronic conditions, psychiatric disorders, or laboratory abnormalities that may increase the risk of study participation 11. Pregnant or lactating women